E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Femoral condyles single lesion from trauma or osteochondritis dissequans with invalidant signs
|
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Compare the clinical improvement of the IKDC subjective score between the microfracture-treated group and the Cartipatch® chondrocyte graft-treated groups 18 months post-operatively |
|
E.2.2 | Secondary objectives of the trial |
• Clinical examination of the knee (KOOS clinical score) and the correlation between IKDC and KOOS • Arthroscopic results of the lesion 18 months post surgery (ICRS) • Percentage of hyaline cartilage at 18 months post operative (histological ICRS comparison) • Comparison of the treated cartilaginous surfaces 18 months post surgery using MRI • Failure rate between the 2 arms (Is considered as a failure: a score lower than 70)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients presenting an osteocartilaginous femoral single lesion, with a traumatic etiology or an osteochondritis dissecans could be included in this trial only if all the following criteria are met: • Patients of both sexes, active, between 18 and 45 years. • Osteochondritis dissecans, type III or IV following the ICRS classification. • Grade 3 or 4 lesion following the ICRS classification. • Lesion’s surface (perpendicular measure: L x l) from 2.50 cm2 to 7.00 cm2 measured following debridment during the arthroscopy. • Lesion’s depth should not be over 10 mm. • Existence of invalidating symptoms, clinically significant (subjective IKDC score lower than 55). • No prior surgical treatment of this lesion such as microfracture according to Pridie method or perforation > 4mm validated by MRI and osteochondral autografts or autologous chondrocytes implantation.
|
|
E.4 | Principal exclusion criteria |
• • Pregnant or breast-feeding women. It will then be required for women in age of giving birth to conduct a pregnancy test before recruiting for the study and to take contraception recognized as efficient. • Anaphylactic reaction history to gentamicin and amphotericin B. • Femoral osteocartilaginous lesion showing a kissing lesion on the tibial plateau or the patella. • Knee varus or valgus > 6° • Any symptomatic affection of the patella. • Existence of an arthrosis, rheumatoid arthritis or any other articular knee affection (meniscal and ligamentary pathology), which, from the surgeon’s opinion, could potentially compromise the evolution of the treatement. • Excessive laxity: Lachman higher than 3 (ICRS). History of one or several crossed ligaments rupture without correction (surgery performed more than 1 year before patient inclusion). • Meniscal pathology history concerning 2/3 of meniscus without treatment (surgery performed more than 1 year before patient inclusion). • Existence of an ulcerous pathology, tuberculosis, a psychiatrically evaluated pathology or a disease requiring a long-term treatment, including drugs acting on the joint or bone metabolism. • Patients suffering present and passed bone, cartilage, muscle or adipose tissue cancer. • Patients with positive serological tests for HIV, Hepatitis B and C, HTLV and Syphilis. • Patients Body Mass Index higher than 30.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Compare at 18 months the clinical improvement of the IKDC subjective score between the two groups |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
overdrowing of the protocol additional patients will be included to compensate potential lost of follow up. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |